Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Advertisement
Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

 

Commercial North America

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?

Leadership Strategy

Bucking Biosimilar Threat, Roche Sees Further Growth

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

Cancer Neurology

Investigating Big Pharma Licensing Trends

AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.

Deals Market Intelligence

AZ, Novartis, Roche Take Part In UK’s Big Data Push

Seven hubs will bring together data sets and help accelerate clinical trials.

 

 

Digital Health United Kingdom

Roche Mounts NMOSD Challenge To Alexion’s Soliris

Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.

Neurology Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register